Valneva’s (VALN) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (d-) rating on shares of Valneva (NASDAQ:VALN) in a research note released on Wednesday,Weiss Ratings reports.

VALN has been the topic of a number of other research reports. Jefferies Financial Group set a $14.00 target price on Valneva and gave the company a “buy” rating in a research note on Monday, August 25th. Wall Street Zen upgraded Valneva to a “hold” rating in a research note on Saturday, September 6th. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Valneva in a research note on Monday, August 25th. Finally, Guggenheim lowered their target price on Valneva from $14.00 to $13.00 and set a “buy” rating on the stock in a research note on Monday, September 8th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Valneva Stock Performance

Shares of VALN stock opened at $10.37 on Wednesday. Valneva has a 1-year low of $3.62 and a 1-year high of $12.25. The company has a current ratio of 2.27, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $891.09 million, a price-to-earnings ratio of -10.58 and a beta of 1.86. The stock’s fifty day simple moving average is $9.86 and its 200-day simple moving average is $7.61.

Valneva (NASDAQ:VALN) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.11. Valneva had a negative return on equity of 34.78% and a negative net margin of 33.87%.The business had revenue of $54.84 million for the quarter, compared to the consensus estimate of $46.28 million. On average, sell-side analysts predict that Valneva will post 0.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Valneva

Large investors have recently made changes to their positions in the business. Marex Group plc acquired a new position in shares of Valneva during the 2nd quarter worth about $64,000. GAMMA Investing LLC bought a new position in Valneva during the first quarter valued at about $94,000. Finally, Frazier Life Sciences Management L.P. bought a new position in Valneva during the second quarter valued at about $8,240,000. Institutional investors and hedge funds own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.